Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04655352
Other study ID # BCT-100-000
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 28, 2015
Est. completion date December 17, 2015

Study information

Verified date January 2022
Source BIO-CAT Microbials, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a single-blind, placebo-lead in design examining the safety and tolerability of a probiotic, Bacillus subtilis MB40. Subjects received a 7-day placebo BID lead-in and a 21-day BID course of Bacillus subtilis MB40. GI questionnaires and Bristol stool charts along with evaluation of any medically significant changes, based on physical examination findings, clinical laboratory tests and vital signs assessments were used to determine the safety and tolerability of MB40.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 17, 2015
Est. primary completion date December 17, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Normal, healthy adult volunteers aged 18 to 55 years. 2. BMI of 18 to 32 kg/m2 (inclusive) 3. Have no clinically significant findings on screening evaluations (clinical, laboratory) 4. If female, participant is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: - Hormonal contraceptives (stable for 1 month) including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) - Double-barrier method - Intrauterine devices - Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) - Vasectomy of partner (shown successful as per appropriate follow-up) 5. Able to comprehend and willing to sign an Informed Consent Form (ICF). Exclusion Criteria: 1. History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders. 2. Current or recent history (<30 days prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection. 3. Frequent GERD, indigestion, nausea, or vomiting (1 or more days per week). 4. Frequent abdominal pain/cramps or bloating (1 or more days per week). 5. Frequent constipation, diarrhea, or alternating constipation/diarrhea (1 or more days per week). 6. Abdominal pain before bowel movements that is relieved with defecation (most bowel movements). 7. Abdominal complaints often worsened by worry or tension (1 or more days per week). 8. Medical diagnosis of esophagitis, gastritis, ulcers, inflammatory bowel disease, gastrointestinal cancer, celiac disease, or irritable bowel syndrome. 9. Recent gastrointestinal bleeding (hematemesis, hematochezia, melena in past 3 months) or anemia in the past 3 months. 10. Unintentional weight loss of 10 lbs or more in the past 3 months. 11. Screening GI Questionnaire Score of = 4 for any single item. 12. Current clinically significant viral infection 13. History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin 14. Resting heart rate less than 45 bpm or greater than 100 bpm. 15. History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure >150/90 mm Hg) 16. History of stomach or intestinal surgery, except that appendectomy and/or cholecystectomy will be allowed. 17. Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g., Crohn's disease or chronic pancreatitis) 18. History of alcoholism or drug addiction within 1 year prior to Screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations. 19. Use of any tobacco-containing or nicotine-containing products (including cigarette, pipe, cigar, chewing tobacco, nicotine patch, or nicotine gum) more frequently than 50 cigarettes per week within 2 months prior to Screening or > 20 per week from screen through the end of the study 20. Current treatment or treatment within 30 days or 5 half-lives (t ½) prior to the first dose of study product with another investigational product or current enrollment in another investigational drug protocol at the time of screening. 21. Use of any over-the-counter, prescription, non-prescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations), within 7 days prior to study entry, unless deemed acceptable by the Investigator. 22. Use of greater that 2 units per day of alcohol-containing or caffeine-containing foods or beverages within 72 hours prior to study entry and throughout the duration of the study. 23. Donation of blood in excess of 500 ml within 4 weeks prior to study entry or of plasma within 2 weeks prior to Screening. 24. Receipt of blood products within 3 months prior to study entry. 25. Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Bacillus subtilis MB40
1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
BIO-CAT Microbials, LLC Prism Research LLC

References & Publications (1)

Spears JL, Kramer R, Nikiforov AI, Rihner MO, Lambert EA. Safety Assessment of Bacillus subtilis MB40 for Use in Foods and Dietary Supplements. Nutrients. 2021 Feb 25;13(3). pii: 733. doi: 10.3390/nu13030733. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Frequency of bowel movements Bristol Stool Chart questionnaire 4 weeks
Other Incidence of clinically significant abnormal vital signs Screening and day 29
Other Incidence of clinically significant abnormal complete blood panel Screening and day 29
Primary Occurrence of adverse events GI Questionnaire and weekly in person assessment of adverse events 4 weeks
Secondary Weekly mean of daily frequency of GI symptoms GI symptom frequency and severity questionnaire 4 weeks
Secondary Weekly mean of daily severity of GI symptoms GI symptom frequency and severity questionnaire 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05445440 - A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine Phase 1
Completed NCT03712540 - An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants Phase 1
Completed NCT03649165 - A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants Phase 1
Completed NCT05956002 - A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants Phase 1
Completed NCT05539976 - A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants
Withdrawn NCT04558216 - Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants Phase 1
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT06097390 - A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III Phase 1
Completed NCT05546151 - A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent Phase 1
Completed NCT05056246 - Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants Phase 1
Completed NCT04390776 - Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules. Phase 1
Completed NCT05074459 - A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines Phase 1
Enrolling by invitation NCT06089109 - Creating VIP Corps to Reduce Maternal Deaths N/A
Completed NCT05996250 - Tolerance of an Immersive Virtual Reality Task Evaluating the Spatial Memory of Elderly Subjects N/A
Completed NCT03278080 - Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1 N/A
Completed NCT05064800 - PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants Phase 1
Completed NCT04471298 - A Study of Qishenyiqi Dripping Pills in Healthy Participants Phase 1
Completed NCT04914936 - A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196 Phase 1
Completed NCT02563262 - Human Neutral Body Posture in Weightlessness N/A
Completed NCT01681186 - A Study of LY2940680 in Healthy Participants Phase 1

External Links